Tags : Research Agreement

Daiichi Sankyo Signs a Research Agreement Gustave Roussy for DS-1062

Shots: Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical, translational, and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively The research program includes two P-II studies evaluating the efficacy, safety, and markers of response and resistance to DS-1062 & patritumab deruxtecan in […]Read More

Takeda Signs an Exclusive License and Research Agreement with Debiopharm

Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program. The candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the […]Read More

MSD Signs a Two-Year Research Agreement with Almac to Discover

Shots::stosohSthShots: Almac to receive upfront, research funding, development and commercial milestones along with the royalties on sales of products emerging from the collaboration. MSD will be responsible for conducting lead optimization, pre/clinical development and commercialization The collaboration will utilize Almac’s unique Ubi-Plex platform to identify and develop novel inhibitors against specified DUBs and will initially […]Read More

Sarepta Signs a Research Agreement with the US Department of

Shots: Sarepta and USAMRIID have entered into a CRADA to jointly identify antisense oligonucleotides utilizing Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform with activity against SARS-CoV-2 for the potential treatment of COVID-19 Sarepta will design, synthesize and manufacture multiple peptide-conjugated PMO (PPMO) constructs based on genetic sequencing of SARS-CoV-2 while USAMRIID will assess the constructs on […]Read More

Lilly Signs a Worldwide License and Research Agreement with Sitryx

Shots: Sitryx to receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies, including Sitryx’s two lead projects The companies will collaborate for 5yrs. supporting the development of therapies with Sitryx to be […]Read More

Gemini Therapeutics Signs a Research Agreement with SERI to Identify

Shots: SERI and Gemini will investigate the link b/w genetic & potential biomarkers in patients with PCV. The collaboration leverages Gemini’s experience of precision medicine to develop therapies targeting the genetically defined patients The agreement explores the molecular impact of specific genes linked to PCV which provide information in designing new therapies in future Gemini […]Read More

Kymera Signs a DNA-Encoded Library Based Drug Discovery Research Agreement

Shots: HitGen to receive upfront and milestones from Kymera. The companies collaborated to identify small molecule leads against targets of interest to Kymera HitGen will leverage its platform technology based on DNA-encoded libraries (DEL) to discover compounds, that will be exclusively licensed to Kymera HitGen’s DELs include encoded syntheses for hundreds of millions of novels, […]Read More

AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate

Shots: AbbVie and Idera collaborated to conduct clinical study evaluating the combination of ABBV-368 + tilsotolimod + CT or ABBV-181. AbbVie will be responsible for conducting the trial while Idera to provide clinical trial supply of tilsotolimod The P-Ib study will evaluate the safety, tolerability, PK and preliminary efficacy of ABBV-368 plus tilsotolimod in three […]Read More

Spring Bank Signs a Research Agreement with the University of

Shots: Spring Bank enters into a collaboration with the University of Texas Southwestern Medical Center for the evaluation of Spring Bank’s STimulator of INterferon Gene (STING) antagonist compounds in autoimmune disease models Spring Bank will evaluate novel STING antagonist compounds in mouse models of autoimmune and inflammatory diseases to meet the unmet medical need for […]Read More